C83.27 Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, spleen

Name of the Condition

• Mixed small and large cell (diffuse) non-Hodgkin's lymphoma, spleen
• Also known as ICD-10 code C83.27

Summary

Mixed small and large cell (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of both small and large lymphoid cells in a diffuse pattern. It typically involves abnormal growth of B-cells or T-cells in the spleen, without forming follicular structures. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific cell composition and distribution.

Causes

The exact cause of mixed small and large cell (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in lymphoid cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Enlarged spleen (splenomegaly).
• Abdominal discomfort or fullness.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.

Diagnosis

Diagnosis typically involves a combination of physical examination, imaging studies (e.g., CT or MRI of the abdomen), and biopsy of the spleen or affected lymph nodes. Laboratory tests, including blood counts and flow cytometry, may help identify abnormal cell populations. Histopathological analysis is essential to confirm the mixed small and large cell subtype and rule out other lymphoma types.

Treatment Options

Treatment depends on the stage, patient health, and lymphoma characteristics. Options may include chemotherapy, immunotherapy, targeted therapy, or splenectomy. Radiation therapy may be used for localized disease. Treatment plans are often individualized and may involve a multidisciplinary team.

Prognosis and Follow-Up

Prognosis varies based on factors like disease stage, cell type, and response to treatment. Regular follow-up with imaging and blood tests is important to monitor for recurrence or progression. Long-term surveillance is recommended, as late effects or secondary malignancies can occur.

Complications

• Splenic rupture (rare but serious).
• Cytopenias (low blood cell counts) due to bone marrow involvement.
• Increased infection risk from impaired immune function.
• Transformation to a more aggressive lymphoma subtype.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid known carcinogens, such as tobacco or excessive alcohol.
• Manage chronic infections (e.g., hepatitis) with appropriate medical care.
• Stay up-to-date with vaccinations, especially if immunosuppressed.

When to Seek Professional Help

Seek medical attention if you experience persistent abdominal pain, unexplained weight loss, fever, or fatigue. Prompt evaluation is important if splenomegaly is suspected or if symptoms worsen.

Tips for Medical Coders

Code C83.27 is specific to mixed small and large cell (diffuse) non-Hodgkin's lymphoma involving the spleen. Documentation should clearly indicate the site (spleen) and histological subtype. Ensure the diagnosis aligns with pathology reports and clinical findings to support accurate coding.